News Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 12/06/2026 BST			After hours 00:56:42
444.92 ^USD	-0.03%		444.84	-0.02%

06-11	Vertex's Late-Stage Clinical Data of Casgevy Deliver Crisis-Free, Transfusion-Free Results in Kids With Blood Disorders	MT
06-11	Vertex Pharmaceuticals Incorporated Presents New Data on Casgevy and Announces Additional Global Regulatory Submissions	CI

All News

Mentions Relevance

06-11	Vertex's Late-Stage Clinical Data of Casgevy Deliver Crisis-Free, Transfusion-Free Results in Kids With Blood Disorders	MT
06-11	Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions	BU
06-11	Vertex Pharmaceuticals Incorporated Presents New Data on Casgevy and Announces Additional Global Regulatory Submissions	CI
06-10	Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 11:20 AM
06-09	Vertex Pharmaceuticals Insider Sold Shares Worth $785,250, According to a Recent SEC Filing	MT
06-05	Vertex Pharmaceuticals Incorporated Presents New Data On ALYFTREK And TRIKAFTA At European Cystic Fibrosis Conference	CI
06-05	Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference	BU
06-03	Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10	BU
06-02	Vertex Pharmaceuticals Insider Sold Shares Worth $888,300, According to a Recent SEC Filing	MT
06-01	Vertex announces US FDA acceptance of biologics license application for accelerated approval of povetacicept in IgA nephropathy	RE
06-01	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy	BU
06-01	Vertex Pharmaceuticals Incorporated Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy	CI
05-29	Vertex Pharmaceuticals Incorporated Presents at Bernstein 42nd Annual Strategic Decisions Conference, May-29-2026 09:00 AM
05-21	Vertex Pharmaceuticals Says New Pain Management Drug Is Under Review at Health Canada	DJ
05-21	Vertex Says Health Canada Accepts Suzetrigine Application for Review	MT
05-21	Vertex Pharmaceuticals Announces New Drug Submission for Suzetrigine Accepted for Review by Health Canada	CI
05-19	Vertex Pharmaceuticals Insider Sold Shares Worth $613,971, According to a Recent SEC Filing	MT
05-19	Vertex Pharmaceuticals Incorporated Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 02:35 PM
05-15	Daiwa Securities Adjusts PT on Vertex Pharmaceuticals to $555 From $561, Maintains Buy Rating	MT
05-13	Declaration of Voting Results by Vertex Pharmaceuticals Incorporated	CI
05-11	Vertex to Participate in Upcoming May Investor Conferences	BU
05-07	Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany	AQ
05-06	Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany	BU
05-06	Vertex Pharmaceuticals Incorporated Signs Reimbursement Agreement for Casgevy in Germany	CI
05-05	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q)	PU